

Publications

Our Impact.



hoosier oncology group

leading cancer research, close to home

TABLE OF CONTENTS

BLADDER	3
BREAST	4
ESOPHAGEAL	5
GASTROINTESTINAL	6
GYNECOLOGIC	9
HEAD & NECK	10
HEMATOLOGY	11
LYMPHOMA	12
MYELOMA	12
PROSTATE	13
QUALITY OF LIFE	15
RENAL	17
THORACIC	18
TRIAL MANAGEMENT	26

BLADDER

MANUSCRIPTS

Jinxing Li, Beth Juliar, Constantin Yiannoutsos, Rafat Ansari, Edward Fox, Michael J. Fisch, Lawrence H. Einhorn, and Christopher J. Sweeney. Weekly Paclitaxel and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium: A Phase II Hoosier Oncology Group Study. *J Clin Oncol* 2005;23 1185-1191

PRESENTATIONS

R. Parameswaran, Indiana University, Walther Cancer Institute, M. Fisch, M.D. Anderson Cancer Center, Walther Cancer Institute, C. Sweeney, L. Einhorn, Indiana University, Walther Cancer Institute. A Hoosier Oncology Group Phase II Study of Weekly Paclitaxel and Gemcitabine in Advanced Transitional Cell Carcinoma (TCC) of the Bladder. Accepted as a poster presentation for ASCO annual meeting May 12-15, 2001, San Francisco, CA.

Jinxing Li MD, Beth Juliar MA MS, Rafat Ansari MD, Edward Fox MD, Michael Fisch MD, Lawrence Einhorn MD, Christopher Sweeney MD. A Phase II Study of Weekly Paclitaxel (P) and Gemcitabine (G) in Advanced Transitional Cell Carcinoma (TCC) of the Urothelium): A Hoosier Oncology Group Study. Poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL

Christopher J. Sweeney, Bruce J. Roth, Donald S. Kaufman, Steven J. Nicol A Phase II Study of ALIMTA in Patients with Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium): A Hoosier Oncology Group Study. Poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL

N.M. Hahn, W.M. Stadler, R.T. Zon, D. Waterhouse, J. Picus, S. Nattam, C.S. Johnson, S.M. Perkins, C.J. Sweeney. A Multicenter Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) As First-Line Chemotherapy for Metastatic Urothelial Carcinoma (UC); Hoosier Oncology Group GU04-75. Accepted for oral presentation (abstract #5018) at the ASCO annual meeting May 29-June 2, 2009, Orlando, FL

BREAST

MANUSCRIPTS

Roth BJ, Sledge GW, Williams SD, Meyer SC, Ansari R, Fisher WB: Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M-VAC) in Metastatic Breast Cancer: A Phase II Trial of the Hoosier Oncology Group. *Cancer* 68: 248-252, 1991.

Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Monaco F, Seshadri R, Sledge Jr G. Randomized Pilot Trial of Combination Versus Sequential Taxotere (T) and Doxorubicin (D) as Primary Chemotherapy for Breast Cancer: A Hoosier Oncology Group Trial. *American Society of Clinical Oncology* 17: No. 10 (October), 1999: pp3033-3037

Soule SE, Miller KD, Porcu P, Ansari R, Fata F, McClean JW, Zon R, Sledge GW, Einhorn LH. Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer. *Annals of Oncology* 13: 1612-1615, 2002.

SUBMITTED FOR PUBLICATION

KD, Sisk J, Gize G. Phase II Study of Gemcitabine, Paclitaxel and Trastuzumab in Metastatic Breast Cancer: A Hoosier Oncology Group Study. *Breast Cancer Res Treat* 2002; 76(suppl 1):S113.

Pablo M. Bedano, Jamil Khatri, Robin Zon, John McClean, Naveed Chowhan, William Fisher, Sang Huh, Michael Titzer, Constantin Yiannoutsos, Kathy D. Miller: A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients with Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60. Accepted October 2007 for publication by Investigational New Drugs (Publication Pending)

ABSTRACTS

Roth BJ, Sledge GW, Williams SD, Fisher WB, Meyer SC: Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M-VAC) as First Line Chemotherapy in Metastatic Breast Cancer: A Phase II Trial of the Hoosier Oncology Group. *Proc Am Soc Clin Oncol* 7: 31, 1988.

Sledge GW, Jr., Stevens W, Sciortino D, Ansari R, Einhorn LH: Carboplatin and WR-2721 as First-Line Chemotherapy for Metastatic Breast Cancer (MBC): A Hoosier Oncology Group Study. *Breast Cancer Research and Treatment meeting* 1991, San Antonio, TX.

McCaskill-Stevens W, Ansari R, Fisher W, Pennington K, Dobbs C, Gonin R, Schafer S, Loesch D, Sledge G. A Hoosier Oncology Group Phase II Study of Biweekly Cisplatin (C) and Paclitaxel (P) in the Treatment of Metastatic Breast Cancer: A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial. Accepted to the ASCO Annual Meeting May 18-21, 1996, Philadelphia, PA.

Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Sledge Jr G. Randomized Pilot Trial of Taxotere (T) and Doxorubicin (D) as Primary Chemotherapy for Breast Cancer: A Hoosier Oncology Group (HOG) Trial (BRE96-1) and Walther Cancer Institute, Indianapolis, IN accepted to the ASCO annual meeting May 15-18, 1999, Atlanta, GA

BREAST (cont.)

PRESENTATIONS

Kathy D. Miller, Judy Sisk, Gary Gize, Sreenivasa Nattam, Rafat Ansari, Jake Vinson and George Sledge. Phase II study of gemcitabine, paclitaxel and trastuzumab in metastatic breast cancer; a Hoosier Oncology Group trial. Presented at the San Antonio Breast Cancer Symposium, December 11-14, 2002.

I. Krop, K. Miller, R. Zon, S. Isakoff, C. Schneider, M. Yu, C. Johnson, L. Vaughn, T. Shonukan, G. Sledge. A Phase II study of Oral Enzastaurin in Patients with Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane-Containing Regimen. Accepted as an oral presentation at the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL

ESOPHAGEAL

ABSTRACTS

M. M. Sgroi, N. Hanna, A. McCollum, N. Bechar, M. DiMaio, Z. Hammoud, M. Yu, H. Choy, C. Beccera. Pre-Operative Cetuximab and Radiation (XRT) for Patients (pts) with Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas: A Pilot Study from the Hoosier Oncology Group and the University of Texas-Southwestern. Accepted to the general poster session at the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL

A.K. Agarwala, N. Hanna, A. McCollum, N. Bechar, M. DiMaio, M. Yu, Y. Tong, C.R. Beccera, H.Choy. Pre-operative Cetuximab and Radiation (XRT) for Patients (pts) with Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas: A Pilot Study from the Hoosier Oncology Group (HOG) and the University of Texas-Southwestern. Accepted to the general poster session (abstract #4557) at the ASCO annual meeting May 29-June 2, 2009, Orlando, FL

GASTROINTESTINAL

MANUSCRIPTS

Loehrer PJ, Turner S, Kubilis P, Hui S, Correa J, Ansari R, Stephens D, Woodburn R, Meyer S: A Prospective Randomized Trial of Fluorouracil Versus Fluorouracil plus Cisplatin in the Treatment of Metastatic Colorectal Cancer: A Hoosier Oncology Group Trial. *J Clin Oncol* 6: 642-48, 1988.

Lauer RC, Fisher WB, Pennington K, Ansari R, Einhorn LH, Loehrer PJ: Etoposide and Split Dose-Cisplatin in Bronchogenic Carcinoma. *Am J Clin Oncol* 11: 634-5, 1988.

Mantravadi RVP, Miller M, Ashley-Lee J, Fisher W, Ansari R, Loehrer PJ: Prophylactic ³²P Chromic Phosphate Therapy of the Liver in Completely Resected Modified Duke's Stage C Colon Cancers: A Hoosier Oncology Group Study. In: Salmon, S. ed. *Adjuvant Treatment of Cancer*. 1990: 446-453.

Miller K, Loehrer PJ, Gonin R, Weber G, Ansari R, Pletcher W, McClean J, Spiridonidis CH, Mortimer J: Phase II Study of Weekly Oral Methotrexate and Zidovudine (AZT) in Advanced Adenocarcinoma of the Pancreas and Hepatocellular Carcinoma. *Invest New Drugs* 14: 207-212, 1996.

Bandealy M, Gonin R, Loehrer P, Monaco F, Einhorn L. A Prospective Randomized Trial of 5-Fluorouracil versus 5-Fluorouracil plus Levamisole in the Treatment of Metastatic Colorectal Cancer. *Clinical Cancer Research* 4: 935-939, 1998.

Ganjoo Kristen N., **Gordon** Michael S., Sandler Alan B., Warner Ruth E., Fife Karen, Poirier Shelley, Seshadri Roopa, Loehrer Patrick J. A Phase I Study of Weekly Gemcitabine and Docetaxel in Patients with Advanced Cancer: A Hoosier Oncology Group Study. *Oncology* 2002; 62: 299-304.

Schneider B, Ganjoo K, Seitz D, Picus J, Fata F, Stoner C, Calley, C, Loehrer P. Phase II study of gemcitabine and docetaxel in combination for advanced pancreatic cancer-a Hoosier Oncology Group study. *Oncology*. 65(3): 218-23, 2003.

SUBMITTED FOR PUBLICATION

Chong-Xian Pan MD, Ph.D, Patrick Loehrer MD, David Seitz MD, Paul Helft MD, Beth Juliar, Rafat Ansari MD, William Pletcher MD, and Christopher Sweeney MD. A Phase II Trial of Irinotecan, 5-Fluorouracil, Leucovorin, combined with Celecoxib and Glutamine as first line therapy for advanced colorectal cancer. *Oncology* 2005; 69: 63-70.

ABSTRACTS

Mantravadi RVP: Prophylactic ³²P Chromic Phosphate Therapy of Liver in Completely Resected Colon Cancers - Preliminary Results of a Phase III Study. *Proc Amer Endocrine Therapy Society* (1988).

GASTROINTESTINAL(cont.)

Mortimer J, Weber G, Fracasso P, Pletcher W, Ansari R. Phase I-II Study of Zidovudine (AZT) and Methotrexate (MTX) in Advanced Pancreatic Cancer and Hepatoma: A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial. Accepted to the ASCO Annual Meeting, May 14th - 17th, 1994, Dallas, Texas.

Picus J, Dickerson G, Logie K, Ansari R, Markham R, Spiridonidis C. A Phase II Study of Unresectable Pancreatic Cancer Treated with 5-FU and Leucovorin with Radiation Therapy: A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial. Accepted to the ASCO Annual Meeting, May 14th - 17th, 1994, Dallas, Texas

Bandealy MT, Gonin R, Loehrer PJ, Einhorn LH. A Prospective Randomized Hoosier Oncology Trial of 5-Fluorouracil versus 5-Fluorouracil Plus Levamisole in the Treatment of Metastatic Colorectal Cancer: A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial. Accepted to the ASCO Annual Meeting May 18-21, 1996, Philadelphia, PA.

Christopher Sweeney MD, David Seitz MD, Rafat Ansari MD, William Pletcher MD, Naveed Chowhan MD, Jake Vinson MHA, Cindy Stoner BS; Patrick Loehrer MD;
A Phase II Trial of Irinotecan (I), 5-Fluorouracil (F), Leucovorin (L) (IFL), Celecoxib and Glutamine as First Line Therapy For Advanced Colorectal Cancer: A Hoosier Oncology Group Study. Accepted to the ASCO annual meeting May 18-21, 2002, Orlando, FL

Chong-Xian Pan MD, Patrick Loehrer MD, Beth Juliar, Rafat Ansari MD, William Pletcher MD, Christopher Sweeney MD. A Phase II Trial of Irinotecan (I), 5-Fluorouracil (F), Leucovorin (L) (IFL), Celecoxib and Glutamine as First Line Therapy For Advanced Colorectal Cancer (CRC): A Hoosier Oncology Group Study. Submitted to the ASCO annual meeting May 31-June 3, 2003, Chicago, IL

Prasad Mantravadi MD, Naomi Fineberg PhD, Rafat Ansari MD, Edward Fox MD, Paul Helft MD, Kenneth Kesler MD, Nasser Hanna MD, Lawrence Einhorn MD, Cindy Stoner, Ramaswamy Govindan MD. A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC): Preliminary Results from the Hoosier Oncology Group (HOG). Supplement Oncology News International, October 2003.

A. M. Moore, H. Cardenes, C. S. Johnson, P. Helft, D. Seitz, A. Stephens, D. Fritz Tai, P. J. Loehrer. A Phase II Study of Gemcitabine in Combination with Radiation Therapy in Patients With Localized, Unresectable Pancreatic Cancer. Submitted to the ASCO annual meeting June 5-8, 2004, New Orleans, LA.

R Govindan, N. Fineberg, H. McLeod, K. Kesler, N. Hanna, C. Stoner, J. Vinson, R. Mantravadi, L. Einhorn. A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC). Submitted to the ASCO annual meeting June 5-8, 2004, New Orleans, LA.

GASTROINTESTINAL(cont.)

PRESENTATIONS

Loehrer PJ, Turner S, Kubilis P, Correa J, Ansari R, Einhorn LH, Williams SD, Stephens D, Woodburn R, Meyer S: A Prospective Randomized Study of 5-Fluorouracil Alone or with Cisplatin in the Treatment of Metastatic Colorectal Cancer: A Hoosier Oncology Group Trial. Poster presentation at ASCO, Atlanta GA, May 1987. Proc Am Soc Clin Oncol 6: 76, 1987.

Mantravadi RVP, Miller M, Ashley-Lee J, Fisher W, Ansari R, Loehrer PJ: Prophylactic ³²P Chromic Phosphate Therapy of the Liver in Completely Resected Modified Duke's Stage C Colon Cancers: A Hoosier Oncology Group Study. Presentation at Sixth International Conference on the Adjuvant Therapy of Cancer, Tucson, Arizona, March 1990. Proc Am Soc Clin Oncol 9:115, 1990

Bryan P Schneider, Kristen N Ganjoo, Lawrence H Einhorn, Joel Picus, Farid Fata, Patrick J Loehrer, Cindy Stoner. Phase II study of gemcitabine and docetaxel in combination for advanced pancreatic cancer. Accepted as a poster presentation with discussion for ASCO annual meeting May 18-21, 2002, Orlando, FL.

Chong-Xian Pan MD, Patrick Loehrer MD, Beth Juliar, Rafat Ansari MD, William Pletcher MD, Christopher Sweeney MD. A Phase II Trial of Irinotecan (I), 5-Fluorouracil (F), Leucovorin (L) (IFL), Celecoxib and Glutamine as First Line Therapy For Advanced Colorectal Cancer (CRC): A Hoosier Oncology Group Study. Presented at the Glaxo/Smithkline national oncology fellow forum, February 28-March 2, 2003, Miami, FL.

Prasad Mantravadi MD, Naomi Fineberg PhD, Rafat Ansari MD, Edward Fox MD, Paul Helft MD, Kenneth Kesler MD, Nasser Hanna MD, Lawrence Einhorn MD, Cindy Stoner, Ramaswamy Govindan MD. A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC): Preliminary Results from the Hoosier Oncology Group (HOG). Poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL

Chiorean EG, Schiel M, Sanghani S, Yu M, Shen J, Cardenes H, LeBlanc J, Robb B, Loehrer PJ, Harvey J: A Phase II trial of Neoadjuvant Capecitabine plus Irinotecan Followed by Combined Modality Capecitabine and Radiation Therapy for Patients with Locally Advanced Rectal Cancer. Accepted as Poster Presentation at the ASCO GI Symposium, January 25-27, 2008, Orlando, FL

Chiorean EG, Schiel M, Sanghani S, Yu M, Shen J, Cardenes H, LeBlanc J, Robb B, Loehrer PJ, Harvey J: A Phase II trial of Neoadjuvant Capecitabine plus Irinotecan Followed by Combined Modality Capecitabine and Radiation Therapy for Patients with Locally Advanced Rectal Cancer. Poster Presentation at Indiana University Melvin and Bren Simon Cancer Center Cancer Research Day, May 7, 2008, Indianapolis, IN

GYNECOLOGIC

MANUSCRIPTS

Achilles J. Fakiris, Higinia R. Cardenes, David H. Moore, Shailaja R. Reddy, Katherine Y. Look, Constantin T. Yiannoutsos, Marcus E. Randall. Indiana University School of Medicine, Indianapolis, IN. Intraperitoneal radioactive phosphorus (³²P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: A Phase II Hoosier Oncology Group (97-1) study. *Gynecologic Oncology*, 2005; 96: 818-823

Matei D, Emerson RE, Schilder J, Menning N, Baldrige LA, Johnson CS, Breen T, McClean J, Stephens D, Whalen C, Sutton G. Imatinib Mesylate in Combination with Docetaxel for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinomatosis, a Hoosier Oncology Group Trial. *CANCER*, 2008 Aug 15; 113(4):723-32. PMID: 18618737

Daniela Matei, Jeanne Schilder, Gregory Sutton, Susan Perkins, Tim Breen, Check Quon, Carolyn Sidor. Activity of 2 Methoxyestradiol (Panzem® NCD) in Advanced, Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinomatosis, a Hoosier Oncology Group Trial, *Gynecologic Oncology* 115 (2009) 90–96. PMID: 19577796

ABSTRACTS

Montaser Shaheen, John W. McClean, Lawrence H. Einhorn. A Phase II Study of Ifosfamide plus Etoposide in Previously treated Ovarian Cancer, A Hoosier Oncology Group (HOG) Study. Accepted to the ASCO annual meeting May 12-15, 2001, San Francisco, CA

Achilles J. Fakiris, Higinia R. Cardenes, David H. Moore, Shailaja R. Reddy, Katherine Y. Look, Constantin T. Yiannoutsos, Marcus E. Randall. Intraperitoneal radioactive phosphorus (³²P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: A Phase II Hoosier Oncology Group (97-1) study. Accepted at the Society of Gynecologic Oncologists annual meeting February 7-11, 2004, San Diego, CA. *Gynec Oncol*, 92(2004); 439.

PRESENTATIONS

Daniela Matei, Robert E. Emerson, Nancy Menning, Jeanne Schilder, John McClean, Greg Sutton, Doyle Stephens, Misty Witherite, Charles Whalen, David H. Moore. Clinical Activity of Imatinib Mesylate (Gleevec) In Combination with Docetaxel In Patients With Advanced, Platinum-Resistant Ovarian Cancer Or Primary Peritoneal Carcinomatosis. Accepted to the ASCO annual meeting June 2-6, 2006, Atlanta, Georgia

D. Matei, J. Schilder, N. Menning, K. Koneru, G. Sutton. A Phase II, Open-Label, Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Patients with Recurrent or Resistant Epithelial Ovarian Cancer. Accepted for poster presentation at the 2007 AACR (American Association for Cancer Research) -NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22-26, 2007, San Francisco, California.

HEAD AND NECK

MANUSCRIPTS

Sandler A, Saxman S, Bandedy M, Heilman D, Monaco F, McClean J, Arquette M. A Phase II Trial of Ifosfamide in the Treatment of Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck. *Am J Clin Oncol* 21:195-197, 1998.

ABSTRACTS

Bandedy M, Hanna M, Arquette M, McClean J, Monaco F, Sandler A. A Phase II Trial of Ifosfamide in the Treatment of Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck. A Hoosier Oncology Group, The Walther Cancer Institute and Indiana University, Indianapolis, Indiana accepted to the ASCO annual meeting May 17-20, 1997, Denver, CO.

PRESENTATIONS

Arquette MA, Mortimer JE, Loehrer PJ, Mandanas RA. A Phase II Hoosier Oncology Group Trial of interferon Alpha-2b (IFN) added to Cisplatin (CDDP) and 5-Fluorouracil (FU) in Recurrent or Metastatic Head and Neck Cancer: A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial. Accepted to the ASCO Annual Meeting, May 14th - 17th, 1994, Dallas, Texas

HEMATOLOGY

MANUSCRIPTS

Rafat Abonour, MD, Final Report of Toxicity and Efficacy of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone (CTP) for Patients with Relapsed or Refractory Multiple Myeloma: A Hoosier Oncology Group Trial: HEM01-21. The Oncologist, Vol. 12, No. 1, 99-106, January 2007

R Govindan, N. Fineberg, H. McLeod, K. Kesler, N. Hanna, C. Stoner, J. Vinson, R. Mantravadi, L. Einhorn. A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC). Submitted to the ASCO annual meeting June 5-8, 2004, New Orleans, LA.

PRESENTATIONS

Daniel Vaena, Larry Cripe, Lawrence Einhorn, Paul Walker, Kenneth Pennington, Carol Young, Cindy Stoner. Phase II Study of Low-Dose Topotecan in Myelodysplastic Syndromes: A Hoosier Oncology Group (HOG) Study. Accepted as a poster presentation for ASCO annual meeting May 18-21, 2002, Orlando, FL.

Rafat Abonour, Kristen Ganjoo, Christopher Fausel, Constantin Yiannoutsos, Beth E. Juliar, Lisa Wood, Gina Smith, Paul Walker, Larry Cripe. A Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone (CTP) for Patients with Relapsed or Refractory Multiple Myeloma, A Hoosier Oncology Group (HOG) Trial. Accepted as a poster presentation for ASH annual meeting December 6-9, 2003, San Diego, CA.

Final Report of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone (CTP) for Patients with Relapsed or Refractory Multiple Myeloma: A Hoosier Oncology Group Trial: HEM01-21 Accepted as a poster presentation for the 2005 Annual Meeting of the American Society of Clinical Oncology, May 13 - 17, 2005, Orlando, FL, USA.

LYMPHOMA

SUBMITTED FOR PUBLICATION

Kristen N Ganjoo, William Fisher, John McClean, Sang Yoon Huh, Jose Bufill, Sheron Williams, and Larry D Cripe. A Phase II Study of Single Agent Gemcitabine in Relapsed or Refractory Follicular or Small Lymphocytic non-Hodgkin's Lymphomas: A Hoosier Oncology Group Study. *Am J Clin Oncol* 2005; 2 (28): 169-72

MELANOMA

MANUSCRIPTS

Mandanas R, Schultz S, Scullin D, Einhorn, LH: Phase II Trial of Cimetidine in Metastatic Melanoma: A Hoosier Oncology Group Trial. *Am J Clin Oncol (CCT)* 14(5): 307-399, 1991.

Chapman PB, Einhorn LH, Meyers ML, Saxman SB, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM. A Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine Alone in Patients with Metastatic Melanoma: A MSK Cancer Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; University of Pennsylvania Medical Center, Philadelphia, and University of Pittsburgh Medical Center, Pittsburgh, PA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Hoosier Oncology Group, Indianapolis, IN; and ECOG, Boston, MA. *Journal Clinical Oncology*, Vol. 17, number 9, September 1999; pp2745-2751

ABSTRACTS

Munshi NC, Scullin D, Schultz S, Lutz T: Phase II Study of High Dose Cimetidine in Patients with Metastatic Malignant Melanoma. *Proc Am Soc Clin Oncol* 7:976, 1988.

Whittaker T, Schultz S, Rynard S: Phase II Study of Daily Oral VP-16 in Metastatic Melanoma: A Hoosier Oncology Group (HOG) Study. *Proc Am Soc Clin Oncol*, 1992.

Saxman SB, Meyers ML, Chapman PB, Destro AN, Panageas KS, Begg CB, Monaco F, Agarwala SS, Schuchter LM, Ernstoff MS, Einhorn LH, Kirkwood JM, Houghton AN. A Phase III Multicenter Randomized Trial of DTIC, Cisplatin, BCNU and Tamoxifen Versus DTIC Alone in Patients with Metastatic Melanoma: A Hoosier Oncology Group (HOG) Trial (MEL91-1) and Walther Cancer Institute, Indianapolis, IN accepted to the ASCO annual meeting May 15-18, 1999, Atlanta, GA

PROSTATE

MANUSCRIPTS

Saxman S, Ansari R, Drasga R, Miller M, Wheeler B, McClean J, Einhorn L: Phase III Trial of Cyclophosphamide Versus Cyclophosphamide, Doxorubicin and Methotrexate in Hormone-Refractory Prostatic Cancer: A Hoosier Oncology Group Study. *Cancer* 70:2488-2492, 1992.

Hudes G, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Einhorn L, Roth B. Vinblastine Versus Vinblastine Plus Oral Estramustine Phosphate for Patients with Hormone Refractory Prostate Cancer: A Hoosier Oncology Group and Fox Chase Network Phase III Trial. *J.C.O.* Vol 17, No 10 (October), 1999:pp 3160-3166

Sweeney CJ, Monaco F, Jung SH, Wasielewski MJ, Picus J, Ansari RH, Dugan WM, Einhorn LH. A Phase II Hoosier Oncology Group Study of Vinorelbine and Estramustine Phosphate in Hormone Refractory Prostate Cancer. *Annals of Oncology* 13: 435-440, 2002

Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, Johnson CS, Scott-Horton TJ, Li L, McLeod HL, Sweeney CJ. A Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis: A Hoosier Oncology Group Study. *Clin Cancer Res* 2006;12(20) October 15, 2006.

ABSTRACTS

Sweeney C, Monaco F, Hanna M, Wasielewski M, Picus J, Ansari A, Dugan W, Einhorn LH. Phase II Study of Weekly Vinorelbine and Estramustine for Hormone Refractory Prostate Cancer (HRPC). Hoosier Oncology Group (HOG) and Walther Cancer Institute, Indianapolis, IN. Accepted to the ASCO annual meeting May 20-23, 2000, New Orleans, LA

G. Hudes, E. Ross, B. Roth, A. Balsham, P. Loehrer, H. Ramsey, J. Sprandio, M. Entmacher, W. Dugan, R. Ansari, L. Einhorn. Fox Chase Cancer Center, Philadelphia, PA and Hoosier Oncology Group, Walther Cancer Institute, Indianapolis, IN. Improved Survival for Patients with Hormone-Refractory Prostate Cancer Receiving Estramustine-Based Antimicrotubule Therapy: Final Report of a Hoosier Oncology Group and Fox Chase Network Phase III Trial Comparing Vinblastine and Vinblastine Plus Oral Estramustine Phosphate. Accepted to the ASCO annual meeting May 18-21, 2002, Orlando, FL

N.M. Hahn, F. Ademuyiwa, R.T. Zon, T. Jones, W. Dugan, C. Whalen, M. Yu, R. Shanmugam, T. Skaar, C.J. Sweeney. A Multicenter Phase II Study of Pemetrexed for the Treatment of Hormone Refractory Prostate Cancer (HRPC) with Reduced Folate Carrier 1 (RFC1) Pharmacogenetic Analysis: HOG GU03-67. Accepted to the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL

PROSTATE (cont.)

PRESENTATIONS

Drasga R, Ansari R, Rynard S, Wheeler B, McClean J, Einhorn L: A Prospective Randomized Trial of Cyclophosphamide Versus Cyclophosphamide plus Adriamycin plus Methotrexate in Hormone Refractory Prostate Cancer: A Hoosier Oncology Group Study. Slide presentation at ASCO, Washington D.C., May 1990. Proc Am Soc Clin Oncol 9:142, 1990.

Hudes G, Roth B, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Einhorn L. A Phase III Trial of Vinblastine Versus Vinblastine plus Estramustine Phosphate for Metastatic Hormone-refractory Prostate Cancer (HRPC). A Hoosier Oncology Group and the Walther Cancer Institute, Indianapolis, Indiana and the Fox Chase Network, Philadelphia, PA presented at the ASCO annual meeting May 17-20, 1997, Denver, CO.

N. M. Hahn, W. Fisher, R. Langdon, R. Zon, M. Browning, C. Calley, C. J. Sweeney. A Multicenter Randomized Phase II Study of Docetaxel (D) plus Vinorelbine (VRB) and Docetaxel plus Estramustine (EMP) in Combination for the Treatment of Hormone Refractory Prostate Cancer (HRPC): HOG GU-0009. Presented as part of the Scientific Program in the Genitourinary (Prostate) Cancer Poster Discussion, 2005 Annual Meeting of the American Society of Clinical Oncology, May 13 - 17, 2005 in Orlando, FL, USA

Christopher Sweeney, Lacey Dobrolecki, Tomasz Beer, Linda Battiato, Jake Vinson, Robert Hickey. Serum proteomic profiling can distinguish androgen sensitive prostate cancer patients from those with androgen resistant disease. ASCO Multidisciplinary Prostate Cancer Symposium 2005.

QUALITY OF LIFE/CANCER CONTROL

MANUSCRIPTS

Michael J. Fisch, Michael L. Titzer, Jean L. Kristeller, Jianzao Shen, Patrick J. Loehrer, Sin-Ho Jung, Steven D. Passik, and Lawrence H. Einhorn. Assessment of Quality of Life in Outpatients with Advanced Cancer: The Accuracy of Clinician Estimations and the Relevance of Spiritual Well-Being: A Hoosier Oncology Group Study. *Journal of Clinical Oncology*, Vol 21, Issue 14 (July), 2003: 2754-2759

Michael J. Fisch, Patrick J. Loehrer, Jean Kristeller, Steven Passik, Sin-Ho Jung, Jianzhao Shen, Matthew A. Arquette, Mary J. Brames, Lawrence H. Einhorn. Fluoxetine versus Placebo in Advanced Cancer Outpatients: A Double-Blinded Trial of the Hoosier Oncology Group. *Journal of Clinical Oncology*, Vol 21, Issue 10 (May), 2003: 1937-1943.

Passik SD. Navari RM. Jung SH. Nagy C. Vinson J. Kirsh KL. Loehrer P. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. *Cancer Investigation*. 22(3):383-8, 2004.

Rudolph M. Navari, Lawrence H. Einhorn, Steven D. Passik, Patrick J. Loehrer Sr., Cynthia Johnson, M. L. Mayer, J. McClean, Jake Vinson, W. Pletcher; A Phase II Trial of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Hoosier Oncology Group Study; Publisher: Springer-Verlag GmbH ISSN: 0941-4355 (Paper) 1433-7339 (Online) DOI: 10.1007/s00520-004-0755-6 Issue: Online First

Rudolph M. Navari, Lawrence H. Einhorn, , Patrick J. Loehrer Sr., Steven D. Passik, Jake Vinson, John McClean, Naveed Chowhan, Nasser Hanna, Cynthia Johnson: A Phase II Trial of Olanzapine, Dexamethasone and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Hoosier Oncology Group Study. *Support Care Cancer*. 2007 Mar 21: 17375339 (P,S,E,B,D)

ABSTRACTS

R. M. Navari, L. H. Einhorn, P. J. Loehrer, S. D. Passik, J. Vinson, J. McClean, N. Chowhan, N. Hanna, C. Calley, M. Yu. A Phase II Trial of Olanzapine (Zyprexa) and Palonosetron (Aloxi) for the Prevention of Chemotherapy Induced Nausea and Vomiting. Accepted to the ASCO annual meeting June 2-6, 2006, Atlanta, Georgia

PRESENTATIONS

Michael J. Fisch, Patrick J. Loehrer, Steven D. Passik, Jean L. Kristeller, Sin-Ho Jung, Lawrence H. Einhorn. Fluoxetine versus Placebo in Advanced Cancer Outpatients: A Placebo-Controlled, Double-Masked Trial of the Hoosier Oncology Group. Accepted as an oral presentation for ASCO annual meeting May 12-15, 2001, San Francisco, CA.

Michael L. Titzer, Michael Fisch, Jean L. Kristeller, Sin-Ho Jung, Patrick J. Loehrer, Lawrence H. Einhorn. Clinicians' Assessment Of Quality Of Life (QOL) In Outpatients With Advanced Cancer: How Accurate Is Our Prediction? A Hoosier Oncology Group Study. Accepted as an oral presentation for ASCO annual meeting May 12-15, 2001, San Francisco, CA.

QUALITY OF LIFE/CANCER CONTROL (cont.)

Steve Passik, Patrick Loehrer, Rudolph Navari, Cindy Nagy, Jeanette Sawi, SinHo Jung; A Phase I Trial of Olanzapine (ZYPREXA) For the Prevention of Delayed Emesis in Cancer Patients Receiving Chemotherapy: A Hoosier Oncology Group Study. Accepted as a poster presentation for ASCO annual meeting May 18-21, 2002, Orlando, FL.

R. M. Navari, L. H. Einhorn, P. J. Loehrer, S. D. Passik, J. Vinson, M. L. Mayer, W. Pletcher, J. McClean. A Phase II Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients Receiving Chemotherapy. Presented at the ASCO annual meeting June 5-8, 2004, New Orleans, LA.

RENAL

MANUSCRIPTS

Inhorn L, Williams SD, Nattam S, Stephens D: High Dose Cimetidine for Treatment of Metastatic Renal Cell Carcinoma: A Hoosier Oncology Group Study. *Am J Clin Oncol* 15:157-159, 1992.

Murphy BR, Rynard SM, Einhorn LH, Loehrer PJ: A Phase II Trial of Interferon Alpha-2A Plus Fluorouracil in Advanced Renal Cell Carcinoma: A Hoosier Oncology Group Study. *Invest New Drugs* 10:225-230, 1992.

Murphy BR, Rynard SM, Pennington KL, Grosh W, Loehrer PJ. A Phase II Trial of Vinblastine plus Dipyridamole in Advanced Renal Cell Carcinoma: A Hoosier Oncology Group Study. *Am J Clin Oncol(CCT)* 17(1):10-13, 1994.

Zon R, McClean J, Helman D, Ansari R, Picus J, Sandler A, Williams S, Loehrer Sr P. Altretramine For the Treatment of Metastatic Renal Cell Carcinoma: A Hoosier Oncology Group Trial. *Investigational New Drugs* 19(3):229-231, August 2001

ABSTRACTS

Inhorn L, Pennington K, Miller M, Meyer S, Stephens D, Williams S: Phase II Study of High Dose Cimetidine in Renal Cell Carcinoma: A Trial of the Hoosier Oncology Group. *Proc Am Soc Clin Oncol* 8:148, 1989.

Murphy B, Rynard S, Pennington K, Grosh W, Loehrer PJ: A Phase II Trial of Vinblastine (VLB) plus Dipyridamole (DP) in Advanced Renal Cell Carcinoma (RCC): A Hoosier Oncology Group Study. *Proc Am Soc Clin Oncol* 10: 1991.

McClean J, Loehrer P, Picus J, Ansari R, Mitchell E, Reynolds R, Capizzi R. A Phase II Study of Altretramine for the Treatment of Metastatic Renal Cell Carcinoma: A Hoosier Oncology Group (HOG), Walther Cancer Institute, and US Bioscience Trial. Accepted to the ASCO Annual Meeting, May 14th - 17th, 1994, Dallas, Texas.

Picus J, Walker PR, Webb C, Gonin R, Woodruff J, McClean J. A Phase II Hoosier Oncology Group Study of Levamisole in the Treatment of Advanced Renal Cell Cancer: A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial. Accepted to the ASCO Annual Meeting May 18-21, 1996, Philadelphia, PA.

Pennington K, Gordon M, Picus J. A Phase II Trial of Liposomal Doxil in the Treatment of Advanced Renal Cell Cancer: A Hoosier Oncology Group (HOG) Study. A Hoosier Oncology Group and the Walther Cancer Institute, Indianapolis, IN accepted to the ASCO annual meeting May 16-19, 1998, Los Angeles, CA.

PRESENTATIONS

Murphy B, Rynard S, Einhorn L, Loehrer PJ: A Phase II Trial of Interferon Alpha-2A Plus 5-Fluorouracil in Advanced Renal Cell Carcinoma: A Hoosier Oncology Group Study. *Proc Am Fed Clinical Research*: 1991.

THORACIC

MANUSCRIPTS

Einhorn LH, Pennington K, McClean J: Phase II Trial of Daily Oral VP-16 in Refractory Small Cell Lung Cancer: A Hoosier Oncology Group Study. *Semin Oncol* 17:32-35, 1990.

Saxman S, Loehrer PJ, Logie K, Stephens D, Workman F, Scullin D, Einhorn LH, Ansari R: Phase II Trial of Daily Oral Etoposide in Patients with Advanced Non-Small Cell Lung Cancer. *Invest. New Drugs* 9: 253-256, 1991.

Eklund E, Miller M, Ansari R, Fisher W, Einhorn LH: Phase II Trial of High Dose Cisplatin Plus Etoposide Plus Vinblastine in Non-Small Cell Lung Cancer: A Hoosier Oncology Group Study. *Am J Clin Oncol* 14:412-45, 1991.

Loehrer PJ, Rynard SM, Ansari R, Songer J, Pennington K, Einhorn LH: Etoposide Plus Ifosfamide Plus Cisplatin (VIP) in Extensive Small-cell Lung Cancer. *Cancer* 69:669-673, 1992

Mandanas R, Einhorn LH, Wheeler B, Ansari R, Lutz T, Miller ME: Carboplatin (CBDCA) Plus Alpha Interferon in Metastatic Non-Small Cell Lung Cancer: A Hoosier Oncology Group (HOG) Phase II Trial. *Am J Clin Oncol (CCT)* 16(6):519-521, 1993.

Loehrer Sr PJ, Ansari R and Einhorn LH: Extensive Small Cell Lung Cancer: Trials of Indiana University and the Hoosier Oncology Group. *Lung Cancer* 9:41-49, 1993.

Blanke C, Ansari R, Tokars R, Fisher W, Pennington K, Mantravadi R, O'Connor T, Rynard S, Miller M, Einhorn L. A Phase III Trial of Thoracic Irradiation with or without Cisplatin for Locally Advanced Non-small Cell Lung Cancer (NSCLC): A Hoosier Oncology Group Protocol. In: Salmon S ed. *Adjuvant Therapy of Cancer VII*. Philadelphia: JB Lippincott, 1993:125-131.

Faylona EA, Loehrer PJ, Ansari R, Sandler AB, Gonin R, Einhorn LH. Daily Oral Etoposide Plus Ifosfamide Plus Cisplatin for Previously Treated Recurrent Small-Cell Lung Cancer: A Hoosier Oncology Group Trial. *J Clin Oncol* 13:1209-1214, 1995.

Blanke C, Ansari R, Tokars R, Fisher W, Pennington K, Mantravadi R, O'Connor T, Rynard S, Miller M, Einhorn L. A Phase III Trial of Thoracic Irradiation with or without Cisplatin for Locally Advanced Unresectable Non-small Cell Lung Cancer (NSCLC): A Hoosier Oncology Group Protocol. *J of Clin Oncol* 13(6):1425-1429,

Loehrer PJ, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, Einhorn LH: Cisplatin Plus Etoposide With and Without Ifosfamide in Extensive Small-Cell Lung Cancer: A Hoosier Oncology Group Study. *J Clin Oncol* 13:2594-2599, 1995

Einhorn LH, and Loehrer PJ: Hoosier Oncology Group Studies in Extensive and Recurrent Small Cell Lung Cancer. *Semin Oncol* 22:28-31, 1995.

Einhorn LH: Phase II Trial of Gemcitabine Plus Cisplatin in NSCLC: A Hoosier Oncology Group Study. *Semin Oncol* 24:24-26, 1997.

Sandler AB, Nguyen B, Ansari R, McClean J, Fisher W, Einhorn LH: A Phase II Study of Gemcitabine and Cisplatin in Patients with Non-Small Cell Lung Cancer. *Semin Oncol* 24: June, 1997.

THORACIC (cont.)

Sandler A, Blanke C, Monaco F, Carey MA, Ansari R, Fisher B, Spiridonidis CH, Einhorn L, Nichols C. A Phase II Trial of CODE (Cisplatin, Vincristine, Doxorubicin, Etoposide) Plus Granulocyte-Colony Stimulating Factor (G-CSF) in Advanced Non-Small Cell Lung Cancer. *Am J Clin Oncol* 21:294-297, 1998.

Ng E, Sandler A, Robinson L, Einhorn LH. A Phase II Study of Carboplatin Plus Gemcitabine in Advanced Non-Small Cell Lung Cancer (NSCLC). A Hoosier Oncology Group Study. *American Journal Clinical Oncology*, 22(6):550-553, 1999.

Sonpavde G, Ansari R, Walker P, Sciortino D, Gabrys G, Murdock A, Gonin R, Einhorn L. Phase II Study of Doxorubicin and Paclitaxel as Second-Line Chemotherapy of Small-Cell Lung Cancer: A Hoosier Oncology Group Trial. *American Journal of Clinical Oncology*. 23(1):68-70, 2000 Feb.

Hanna NH, Sandler AB, Loehrer Sr. PJ, Ansari R, Jung SH, Lane K, Einhorn LH. Maintenance Daily Oral Etoposide versus No Further Therapy Following Induction Chemotherapy with Etoposide plus Ifosfamide plus Cisplatin in Extensive Small-Cell Lung Cancer: A Hoosier Oncology Group (Randomized) Trial. *Annals of Oncology* 13: 95-102, 2002.

Hanna N, Ansari R, Fisher W, Shen J, Jung S, Sandler A. Etoposide, Ifosfamide and Cisplatin (VIP) plus Concurrent Radiation Therapy for Previously Untreated Limited Small Cell Lung Cancer (SCLC): A Hoosier Oncology Group (HOG) Phase II study. *Lung Cancer* 35 (3): 293-297, 2002.

Sumeet Bhatia, Nasser Hanna, Rafat Ansari, William Pletcher, Lawrence Einhorn, Elizabeth Ng, Alan Sandler. A Phase II Study of Gemcitabine Plus Paclitaxel in Patients With Previously Untreated Stage IIIb and IV Non-Small Cell Lung Cancer. *Lung Cancer* 38 (2002): 73-77.

Sumeet Bhatia, Nasser Hanna, Rafat Ansari, Lawrence Einhorn, Alan Sandler. Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC: A Hoosier Oncology Group (HOG) phase II study. *Lung Cancer* 38 (2002): 85-89.

Hanna N, Shepherd F, Fossella F, Pereira J, De Marinis F, von Pawel J, Gatzemeier U, Tsao T, Pless M, Muller T, Lim H, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn P. Randomized Phase III Trial of Pemetrexed versus Docetaxel in Patients with Non-small Cell Lung Cancer Previously Treated with Chemotherapy. *J Clin Oncol* 2004;22:1589-1597

Nasser Hanna, Paul Bunn, Jr., Corey Langer, Lawrence Einhorn, Troy Guthrie, Jr., Thaddeus Beck, Rafat Ansari, Peter Ellis, Michael Byrne, Mark Morrison, Subramanian Hariharan, Benjamin Wang, Alan Sandler. Randomized Phase II Trial Comparing Irinotecan/Cisplatin with Etoposide/Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer. *J Clin Oncol* 2006; 24:2038-2046

A.M. Moore, L.H. Einhorn, D. Estes, R. Govindan, J. Axelson, J. Vinson, T. E. Breen, M. Yu, N.H. Hanna. Gefitinib in Patients with Chemo-sensitive and Chemo-refractory Relapsed Small Cell Cancers: A Hoosier Oncology Group Phase II Trial. *Lung Cancer* (2006) 52, 93-97

Ademuyiwa F, Johnson C, White A, Breen T, Harvey J, Neubauer M, Hanna N. Prognostic factors in stage III non-small cell lung cancer. *Clin Lung Ca* 2007;8:478-82

THORACIC (cont.)

Anuj Agarwala, William Fisher, Daniel Bruetman, John McClean, David Taber, Michael Titzer, Beth Juliar, Menggang Yu, Tim Breen, Lawrence Einhorn, Nasser Hanna. Gefitinib plus Celecoxib in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. *J Thorac Oncol* 2008;3:374-379.

N. Hanna, M. Neubauer, C. Yiannoutsos, R. McGarry, J. Arseneau, R. Ansari, C. Reynolds, R. Govindan, A. Melnyk, W. Fisher, D. Richards, D. Bruetman, T. Anderson, N. Chowhan, S. Nattam, P. Mantravadi, C. Johnson, T. Breen, A. White, L. Einhorn, Cisplatin plus Etoposide plus Concurrent Chest Radiation with or without Consolidation Docetaxel in Patients with Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Study from the Hoosier Oncology Group and U.S. Oncology. *J Clin Oncol.* 2008 Dec 10;26(35):5755-60. Epub 2008 Nov 10.

Jalal, Shadia MD; Ansari, Rafat MD; Govindan, Ramaswamy MD; Bhatia, Sumeet MD; Bruetman, Daniel MD; Fisher, William MD; Masters, Gregory MD; White, Angela MBA; Stover, Daniel MT ; Yu, Menggang PhD; Hanna, Nasser MD. Pemetrexed in Second Line and beyond Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study. *Journal of Thoracic Oncology.* 4(1):93-96, January 2009.

S. Jalal, D. Waterhouse, M. J. Edelman, S. Nattam, R. Ansari, K. Koneru, R. Clark, A. Richards, J. Wu, M. Yu, B. Bottema, A. White, N. Hanna. Pemetrexed plus Cetuximab in patients with Recurrent Non-Small Cell Lung Cancer (NSCLC): A Phase I/II Study from the Hoosier Oncology Group. *Journal of Thoracic Oncology* • Volume 4, Number 10, October 2009.

ABSTRACTS

Ansari R, Fisher W, Butler F, Pennington K, Drasga R, Sciortino D, Miller M, Einhorn L: Aggressive Chemotherapy of Extensive Non-Small Cell Lung Cancer: A Trial of the Hoosier Oncology Group. *Proc Am Soc Clin Oncol* 8:242, 1989.

Higgs D, Jaussaud J, Miller M: Quality of Life as an Outcome Variable in Clients Receiving Chemotherapy for Lung Cancer. *Proc ONS* (1989).

Miller JC, Loehrer PJ, Songer J, Pennington K, Ansari R, Turner S, Einhorn LH: VP-16, Ifosfamide and Cisplatin (VIP) in Extensive Small Cell Lung Cancer: A Hoosier Oncology Group Study. *Proc Am Soc Clin Oncol* 9:248, 1990.

Saxman S, Logie K, Stephens D, Workman F, Scullin D, Loehrer PJ: Phase II Trial of Daily Oral Etoposide in Patients with Surgically Unresectable Non-Small Cell Lung Cancer. *Proc Am Soc Clin Oncol* 9:142, 1990.

Tokars R, Ansari R, Mantravadi R, Einhorn L, Fisher W, Pennington K, O'Connor T, Rynard S, Miller M: A Phase III Study of Thoracic Radiation With or Without Concurrent Cisplatin Chemotherapy in Locoregional Unresectable Non-Small Cell Carcinoma of the Lung: A Hoosier Oncology Group Protocol. Slide presentation at ASTRO, Washington DC, October 1991.

Faylona E, Loehrer P, Einhorn L, Ansari R, McClean J, Williams S: A Phase II Study of Daily Oral VP-16 + Ifosfamide + Cisplatin for Previously Treated Small Cell Lung Cancer (SCLC): A Hoosier Oncology Group Study (HOG) Trial. *Proc Am Soc Clin Oncol*, 1992.

THORACIC (cont.)

Mandanas RA, Loehrer PJ, Ansari R, Wheeler B, Einhorn LH: Carboplatin (CBDCA) Plus Alpha Interferon (IFNa-2a) in Metastatic Non-Small Cell Lung Cancer (NSCLC): A Hoosier Oncology Group (HOG) Phase II Trial. Proc Am Soc Clin Oncol, 1992.

Sandler A, Nichols C, Rynard S, Ansari R, Blanke C, Einhorn L: A Phase II Hoosier Oncology Group Trial using CODE Chemotherapy in Patients with Unresectable Stage III or IV Non-Small Cell Lung Cancer (NSCLC). Proc Am Soc Clin Oncol, 1993.

Blanke C, Ansari R, Tokars R, Fisher W, Pennington K, Mantravadi R, O'Connor T, Rynard S, Miller M, Einhorn L. A Phase III Trial of Thoracic Irradiation With or Without Cisplatin For Locally Advanced Non-small Cell Lung Cancer (NSCLC): A Hoosier Oncology Group Protocol. Proc Int'l Conference on Adjuvant Therapy of Cancer, 1993.

Sandler A, Loehrer PJ, Ansari R, Gonin R, Wasielewski MJ, Einhorn LH. A Phase III Study of VP16 plus Cisplatin (VP) alone or with Ifosfamide (VIP) in Previously Untreated Patients (PTS) with Extensive Small Cell Carcinoma of the LUNG (SCLC): A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial. Accepted to the Seventh World Conference on Lung Cancer, June 26th - July 1st, 1994, Colorado Springs, Colorado.

Sandler AB, Ansari R, McClean J, Fisher W, Dorr A, Einhorn LH. A Hoosier Oncology Group Phase II Study of Gemcitabine Plus Cisplatin in Non-Small Cell Lung Cancer (NSCLC): A Hoosier Oncology Group and Walther Cancer Institute Trial. Submitted to the ASCO Annual Meeting May 20-23rd, 1995, Los Angeles, California.

Sandler AB, Ansari R, Fisher W, Gonin R, Levy R, Einhorn LH. A Phase II Hoosier Oncology Group Study of VP-16 Plus Ifosfamide Plus Cisplatin (VIP) Plus Concurrent Radiation Therapy (XRT) for Previously Untreated Limited Small Cell Lung Cancer (SCLC). A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial. Accepted to the ASCO Annual Meeting May 18-21, 1996, Philadelphia, PA.

Mantravadi R, Sandler A, Montebello J, Ansari R, McClean J, Nattam S, Walker P, Einhorn L. Randomized Phase III Study of Cisplatin (P) and Vinblastine (V) Followed by Thoracic Radiotherapy With or Without Hydroxyurea (HX) In Previously Untreated Limited Unresectable Non-Small Cell Lung Cancer (NSCLC). A Hoosier Oncology Group and the Walther Cancer Institute, Indianapolis, IN accepted to the ASCO annual meeting May 16-19, 1998, Los Angeles, CA.

Ng E, Sandler A, Einhorn L. A Phase II Study of Carboplatin Plus Gemcitabine in Non-Small Cell Lung Cancer (NSCLC). A Hoosier Oncology Group, Indianapolis, IN accepted to the ASCO annual meeting May 16-19, 1998, Los Angeles, CA.

Sonpavde G, Ansari R, Einhorn L. A Phase II Trial of Bolus Doxorubicin and 3-Hour Paclitaxel as Second-Line Chemotherapy of Small-Cell Lung Cancer: A Hoosier Oncology Group Trial. A Hoosier Oncology Group, Indianapolis, IN accepted to the ASCO annual meeting May 16-19, 1998, Los Angeles, CA.

Sandler A, Nemunaitis J, Dehnam C, Cormier Y, von Pawel J, Niyikiza C, Nguyen B, Einhorn L. Phase III Study of Cisplatin (C) With or Without Gemcitabine (G) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). A Hoosier Oncology Group, Indianapolis, IN, PRN, Dallas, TX, Le Centre de Pneumologie de Laval, Quebec, Zentralkrankenhaus Gauting, Gauting, and Eli Lilly and Co., Indianapolis, IN. Accepted to the ESMO annual meeting November 23, 1998, Athens, Greece.

THORACIC (cont.)

Mantravadi R, Sandler A, Montebello J, Ansari R, Nattam S, McClean J, Walker P, Einhorn L. A Phase III Hoosier Oncology Group Study of Thoracic Radiotherapy (TRT) Plus Cisplatin (P) and Vinblastin (V) With or Without Hydroxycarbamide (HX) for Locally Unresectable Non-Small Cell Lung Cancer (NSCLC). Hoosier Oncology Group and Walther Cancer Institute, Indianapolis, IN. Accepted at the ASTRO annual meeting October 25-28 1998, Phoenix, AZ

Sandler A, Ansari R, Saxman S, Walker P, Wasielewski MJ, Monaco F, Hayes J, Einhorn LH. Phase III Trial of Maintenance Daily Oral VP-16 Versus No Further Therapy Following Induction Chemotherapy With VP-16 (V) Plus Ifosfamide (I) Plus Cisplatin (P) (VIP) In Extensive Small Cell Lung Cancer (SCLC): A Hoosier Oncology Group (HOG) Trial (LUN93-2). Indiana University Cancer Center, Indianapolis, IN; Hoosier Oncology Group and Walther Cancer Institute, Indianapolis, IN. Accepted to the ASCO annual meeting May 15-18, 1999, Atlanta, GA

Bhatia S, Sandler A, Ansari R, Monaco F, Einhorn LH. Phase II Study of Paclitaxel Carboplatin and Radiation Therapy for Locally Advanced or Inoperable Non-Small Cell Lung Cancer (NSSLCL): A Hoosier Oncology Group (HOG) Trial (LUN97-1) and Walther Cancer Institute, Indianapolis, IN. Accepted to the ASCO annual meeting May 15-18, 1999, Atlanta, GA

Bhatia S, Ng E, Ansari A, Bufill J, Litrell D, Monaco F, Hanna M, Einhorn LH and Sandler A. A Phase II Study of Paclitaxel and Gemcitabine in Patients with Advanced Non Small Cell Lung Cancer -A Hoosier Oncology Group (HOG) Trial. Accepted to the ASCO annual meeting May 20-23, 2000, New Orleans, Louisiana.

Moore, A., Estes, D., Govindan, R., Vinson, J., Calley, C., Yu, M., Einhorn, L., Hanna, N.. A Phase II Trial of Gefitinib (Iressa) in Patients With Chemosensitive and Chemorefractory Relapsed Neuroendocrine Cancers. A Hoosier Oncology Group Trial. Presented as part of the Scientific Program in the Lung Cancer General Poster Session 2005 Annual Meeting of the American Society of Clinical Oncology. May 13 - 17, 2005 in Orlando, FL, USA.

A Sandler, C Langer, P Bunn, L Einhorn. Interim Safety Analysis of Irinotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive Small Cell Lung Cancer. Accepted to the ASCO annual meeting May 13-17, 2005 in Orlando, Florida

P. Bedano, M. Neubauer, R. Ansari, R. Govindan, L. Einhorn, D. Bruetman, A. White, T. Breen, B. Juliar, N. Hanna. Phase III Study of Cisplatin (P) plus Etoposide (E) with Concurrent Chest Radiation (XRT) followed by Docetaxel (D) vs. Observation in Patients (pts) with Stage III Non-small Cell Lung Cancer (NSCLC): An Interim Toxicity Analysis of Consolidation Therapy. Presented as part of the Scientific Program in the Lung Cancer General Poster Session 2006 Annual Meeting of the American Society of Clinical Oncology. June 2-6, 2006, Atlanta, Georgia

N. Hanna, R. Ansari, S. Bhatia, R. Govindan, D. Bruetman, M. Guarino, W. Fisher, A. White, T. Breen, B. Juliar. Pemetrexed in Patients (pts) with Relapsed Small Cell Lung Cancer (SCLC): A Phase II Study from the Hoosier Oncology Group. Presented as part of the Scientific Program in the Lung Cancer General Poster Session 2006 Annual Meeting of the American Society of Clinical Oncology. June 2-6, 2006, Atlanta, Georgia

THORACIC (cont.)

A. Agarwala, L. Einhorn, W. Fisher, D. Bruetman, J. McClean, D. Taber, M. Titzer, B. Juliar, T. Breen, N. Hanna. Gefitinib plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC): A Phase II Study from the Hoosier Oncology Group. Presented as part of the Scientific Program in the Lung Cancer General Poster Session 2006 Annual Meeting of the American Society of Clinical Oncology. June 2-6, 2006, Atlanta, Georgia

P. Bedano, M. Edelman, S. Nattam, D. Waterhouse, J. Shen, M. Yu, J. Harvey, J. Vinson, A. White, B. Bottema, N. Hanna. A Phase I-IIa Dose Ranging Study of Pemetrexed plus Cetuximab in Patients (pts) with Recurrent Non-Small Cell Lung Cancer (NSCLC): Analysis of the Completed Phase I Portion of HOG-LUN04-79. Poster presentation at the 4th IASLC International Chicago Symposium on Malignancies of the Chest and Head and Neck, October 26-28, 2006.

F.O. Ademuyiwa, N. Hanna, C. Johnson, T. Breen, C. Yiannoutsos, A. White. Multivariate Analysis of Prognostic Variables Associated with Survival from a Phase III Study of Cisplatin (P) plus Etoposide (E) plus Chest Radiation (XRT) with or without Consolidation Docetaxel (D) in Patients with Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC). Poster accepted to the 7th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, CA – February 22-24, 2007

M. M. Sgroi, M. Neubauer, R. Ansari, R. Govindan, D. Bruetman, W. Fisher, C. Johnson, T. Breen, C. Yiannoutsos, N. Hanna: An analysis of elderly patients (pts) treated on a phase III trial of cisplatin (P) plus etoposide (E) with concurrent radiotherapy (CRT) followed by docetaxel (D) vs observation (O) in pts with stage III non small cell lung cancer (NSCLC). Poster accepted to Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.

F. Ademuyiwa, C. Johnson, A. White, T. Breen, J. Harvey, M. Neubauer, N. Hanna: Prognostic Factors For Survival In Patients With Unresectable Stage III Non-Small Cell Lung Cancer From a Phase III Randomized Trial From The Hoosier Oncology Group. Poster accepted to Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.

V. Cook, N. Hanna, T. Breen, A. White, J. Wu: Predictors of toxicity to consolidation docetaxel (D) following cisplatin (P) plus etoposide (E) plus concurrent radiation (XRT) in patients (pts) with stage III non-small cell lung cancer (NSCLC) treated on a phase III randomized trial. Abstract accepted to Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.

S. Jalal, D. Waterhouse, M. Edelman, S. Nattam, R. Ansari, K. Koneru, M. Yu, J. Shen, T. Breen, N. Hanna: Pemetrexed plus cetuximab in patients (pts) with recurrent non-small cell lung cancer (NSCLC): a phase I-IIa dose-ranging study from the Hoosier Oncology Group. Poster accepted to Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.

S. Jalal, S. Bhatia, L. Einhorn, R. Ansari, N. Bechar, R. Govindan, K. Koneru, P. Bedano, J. Wu, N. Hanna. Paclitaxel (P) plus bevacizumab (B) in patients (pts) with Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy trial from the Hoosier Oncology Group. Accepted to the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL

T. Al Baghdadi, S. Bhatia, W. Harb, J. Maher, J. McClean, S. Nattam, D. Taber, M. Yu, C. Johnson and N. Hanna. Erlotinib and bevacizumab in chemotherapy naive performance status 2 patients with advanced non-small-cell lung cancer. Accepted (abstract #e19082) at the ASCO annual meeting May 29-June 2, 2009, Orlando, FL

THORACIC (cont.)

Barriger RB, FakirisAJ, Hanna N, Yu M, Mantravadi P, McGarry RC. Dose-Volume Analysis of Radiation Pneumonitis in Non-Small-Cell Lung Cancer Patients Treated with Concurrent Cisplatin and Etoposide With or Without Consolidation Docetaxel. *Int J Radiat Oncol Biol Phys*, 2010 Mar 13

PRESENTATIONS

Ansari R, Tokars R, Fisher W, Pennington K, Mantravadi R, O'Connor T, Rynard S, Miller M, Einhorn L: A Phase III Study of Thoracic Irradiation With or Without Concomitant Cisplatin in Locoregional Unresectable Non-Small Cell Lung Cancer (NSCLC): A Hoosier Oncology Group (HOG) Protocol. Slide presentation at the ASCO annual meeting May, 1991 in Houston, TX. *Proc Am Soc Clin Oncol* 10: 1991.

Tokars R, Ansari R, Mantravadi R, Einhorn L, Fisher W, Pennington K, O'Connor T, Rynard S, Miller M: A Phase III Study of Thoracic Radiation With or Without Concurrent Cisplatin Chemotherapy in Locoregional Unresectable Non-Small Cell Carcinoma of the Lung: A Hoosier Oncology Group Protocol. Slide presentation at ASTRO meeting October, 1991 in Washington DC. *Proc ASTRO*: 1991.

Ansari R, Loehrer PJ, Gonin R, Wasielewski MJ, Einhorn LH. A Phase III Study of VP16 plus Cisplatin (VP) alone or with Ifosfamide (VIP) in Previously Untreated Patients with Extensive Small Cell Carcinoma of the Lung (SCLC): A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial. Slide presentation accepted to the ASCO Meeting, May 14-17th, 1994, Dallas, Texas.

Sandler AB, Loehrer PJ, Ansari R, Logie KW, Mortimer J, Sridhar R, Einhorn LH. A Phase II Study of Daily Oral VP-16 Plus Ifosfamide Plus Cisplatin (poVIP) for Previously Treated Recurrent Small Cell Lung Cancer (SCLC): A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial. Poster Presentation accepted to the ASCO Annual Meeting, May 14-17, 1994, Dallas, Texas.

Sandler AB, Ansari R, Fisher W, Gonin R, Levy R, Einhorn LH. A Phase II Hoosier Oncology Group Study of VP-16 Plus Ifosfamide Plus Cisplatin (VIP) Plus Concurrent Radiation Therapy (XRT) for Previously Untreated Limited Small Cell Lung Cancer (SCLC). A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial. Accepted to the World Conference on Lung Cancer August, 1997 Dublin, Ireland.

Nasser H, Hanna, Alan B. Sandler, Patrick J. Loehrer, Sr., Rafat Ansari, Sin-Ho Jung, Kathleen Lane and Lawrence H. Einhorn Maintenance Daily Oral Etoposide Versus No Further Therapy Following Induction Chemotherapy With Etoposide Plus Ifosfamide Plus Cisplatin In Extensive Small Cell Lung Cancer: A Hoosier Oncology Group Study. Accepted as a poster presentation with discussion for ASCO annual meeting May 12-15, 2001, San Francisco, CA.

Nasser Hanna, Frances A Shepherd, Rafael Rosell, Jose R Pereira, Filippo De Marinis, Frank V Fossella, Louis Kayitalire, Sofia Paul, Lawrence Einhorn, Paul A Bunn. A Phase III Study of Pemetrexed vs Docetaxel in Patients with Recurrent Non-Small Cell Lung Cancer (NSCLC) who were Previously Treated with Chemotherapy): A Hoosier Oncology Group Study. Presented at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL

THORACIC (cont.)

Karen Kelly, Nasser Hanna, Arthur Rosenberg, Paul Bunn, Jr., and Michael N. Needle. A Multi-Centered Phase I/II Study of Cetuximab in Combination with Paclitaxel and Carboplatin in Untreated Patients with Stage IV Non-Small Cell Lung Cancer): A Hoosier Oncology Group Study. Poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL

A Sandler, C Langer, P Bunn, L Einhorn A Randomized Phase III Trial Comparing CPT-11 (Irinotecan HCl; Camptosar Injection)/Cisplatin with Etoposide/Cisplatin in Patients with Previously Untreated, Extensive, Small-Cell Lung Cancer: A Hoosier Oncology Group Study. Poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL

A Auferin, C Le Pechoux on behalf of the MAC3-LC Group. Meta-analysis of randomized trials evaluating Cisplatin or carboplatin-based concomitant chemoradiation versus radiotherapy alone in locally advanced non-small cell lung cancer. Presented at the 10th World Conference on Lung Cancer August 10-14, 2003, Vancouver, British Columbia, Canada.

N. Hanna, M. Neubauer, R. Ansari, R. Govindan, D. Bruetman, W. Fische⁶, N. Chowhan, S. Nattam, C. Yiannoutsos, L. Einhorn: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24. Poster presentation at Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.

N. Hanna, M. Neubauer, R. McGarry, C. Johnson, C. Yiannoutso, T. Breen, A. White, R. Ansari, L. Einhorn, R. Govindan: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24. Presentation at 12th World Conference on Lung Cancer, Seoul, Korea September 2-6, 2007.

L. Mina, M. Neubauer, R. Ansari, R. Govindan, L. Einhorn, W. Fisher, D. Bruetman, N. Chowhan, C. Johnson, N. Hanna. Phase III Trial of Cisplatin (P) plus Etoposide (E) plus Concurrent Chest Radiation (XRT) with or without Consolidation Docetaxel (D) in Patients (pts) with Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC): HOG LUN 01-24/USO-023; Updated Results. Accepted as a poster presentation to the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL

R. B. Barriger, J. C. Aseneau, M. Yu, C. Reynolds, P. Mantravadi, M. Neubauer, A. J. Fakiris, A. White, N. Hanna, R. C. McGarry. Rates and Risk of Pneumonitis in Non-Small Cell Lung Carcinoma (NSCLC) Patients (pts) Treated with Concurrent Chemoradiation. Submitted to the ASTRO Annual Meeting, September 21-25, 2008, Boston, MA.

E. M. Casey, W. Harb, D. Bradford, J. Bufill, S. Nattam, J. Patel, W. Fisher, J. E. Latz, J. Wu, N. Hanna. Randomized, Double-Blind, Multicenter, Phase II Study of Pemetrexed (PEM), Carboplatin (CARBO), Bevacizumab (BEV) with Enzastaurin (ENZ) or Placebo (PBO) in Chemo-Naïve Patients with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group (HOG) LUN06-116. Accepted to the general poster session (abstract #8035) at the ASCO annual meeting May 29-June 2, 2009, Orlando, FL.

TRIAL MANAGEMENT

MANUSCRIPTS

Fisher WB, Cohen J, Hammond MK, Turner S, Loehrer PJ: Clinical Trials in Cancer Therapy Efforts to Improve Patient Enrollment by Community Oncologists. Medical and Pediatric Oncology 19:165-168, 1991.

Yu M, Yiannoutsos C: Designs for Phase II Trials with Trade-off between Efficacy and Toxicity. JP Journal of Biostatistics 2007.

PRESENTATIONS

Fisher W, Loehrer PJ, Cohen S, Turner S: Clinical Trials in Cancer Therapy: Efforts to Improve Patient Entry by Community Oncologists. Presentation at ASCO, Atlanta GA, May 1987.

Ashley-Lee J: Taming Data Management. Poster Presentation - Oncology Nursing Society, Annual Meeting, Washington D.C., May 1990.

Jordan L, Arnos S: Patient Assessment and Management in High Dose Rate Brachytherapy. Presentation at Oncology Nursing Society, Annual Meeting, Washington, D.C., May, 1990



hoosier oncology group

leading cancer research, close to home

351 west 10th street, suite 330 | indianapolis, in 46202

p/ 317.921.2052 | f/ 317.921.2053

www.hoosieroncologygroup.org